The hormone nomenclature debate: Is a name change the key to patient safety?
In the latest issue of Clinical Endocrinology News, I found an interesting article reporting a proposal to change the name of a hormone. The rationale for the proposed change was “patient safety.”
In 2009, a patient with known panhypopituitarism was admitted to a U.K. hospital for elective surgery. Diagnosis included panhypopituitarism with diabetes insipidus. The patient developed hypernatremia and volume depletion, tragically leading to pronounced hypotension and death.
The author attributes this …
The hormone nomenclature debate: Is a name change the key to patient safety?












![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)



![Finding peace and reclaiming humanity within a broken health care system [PODCAST]](https://kevinmd.com/wp-content/uploads/058307ba-bb36-43f1-9e3a-6e3100f183b5-190x100.jpeg)



